Selected research
Industry Research
Cardiovascular Disease Drugs Industry Research Report 2026
Market perspective
The global Cardiovascular Disease Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cardiovascular Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cardiovascular Disease Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cardiovascular Disease Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cardiovascular Disease Drugs include Takeda Pharmaceutical, Sanofi, Johnson＆Johnson, Novartis, Merck, Roche, Pfizer, Bayer and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cardiovascular Disease Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cardiovascular Disease Drugs Market by Company
Takeda Pharmaceutical
Sanofi
Johnson＆Johnson
Novartis
Merck
Roche
Pfizer
Bayer
AstraZeneca
United Therapeutics Corporation
Daiichi Sankyo Company Limited
Boehringer Ingelheim
Astellas Pharma
Actelion Pharmaceuticals
Cardiovascular Disease Drugs Segment by Type
Lotrel
Zebeta
Coumadin
Sectral
Heparin
Lopressor
Norvasc
Toprol XL
Others
Cardiovascular Disease Drugs Segment by Application
Stroke
Dyslipidemia
Thrombosis
Peripheral Artery Disease
Asischemic Heart Disease
Coronary Artery Diseases
Atherosclerosis
Others
Cardiovascular Disease Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cardiovascular Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cardiovascular Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cardiovascular Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cardiovascular Disease Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cardiovascular Disease Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cardiovascular Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lotrel
- Zebeta
- Coumadin
- Sectral
- Heparin
- Lopressor
- Norvasc
- Toprol XL
- Others
Applications
- Stroke
- Dyslipidemia
- Thrombosis
- Peripheral Artery Disease
- Asischemic Heart Disease
- Coronary Artery Diseases
- Atherosclerosis
- Others
Companies covered
- Takeda Pharmaceutical
- Sanofi
- Johnson＆Johnson
- Novartis
- Merck
- Roche
- Pfizer
- Bayer
- AstraZeneca
- United Therapeutics Corporation
- Daiichi Sankyo Company Limited
- Boehringer Ingelheim
- Astellas Pharma
- Actelion Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cardiovascular Disease Drugs Market Size (2021-2032)
- 2.2.2 Global Cardiovascular Disease Drugs Sales (2021-2032)
- 2.2.3 Global Cardiovascular Disease Drugs Market Average Price (2021-2032)
- 2.3 Cardiovascular Disease Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Lotrel
- 2.3.3 Zebeta
- 2.3.4 Coumadin
- 2.3.5 Sectral
- 2.3.6 Heparin
- 2.3.7 Lopressor
- 2.3.8 Norvasc
- 2.3.9 Toprol XL
- 2.3.10 Others
- 2.4 Cardiovascular Disease Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Stroke
- 2.4.3 Dyslipidemia
- 2.4.4 Thrombosis
- 2.4.5 Peripheral Artery Disease
- 2.4.6 Asischemic Heart Disease
- 2.4.7 Coronary Artery Diseases
- 2.4.8 Atherosclerosis
- 2.4.9 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cardiovascular Disease Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cardiovascular Disease Drugs Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Cardiovascular Disease Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Cardiovascular Disease Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Cardiovascular Disease Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cardiovascular Disease Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cardiovascular Disease Drugs, Product Type & Application
- 3.8 Global Manufacturers of Cardiovascular Disease Drugs, Established Date
- 3.9 Global Cardiovascular Disease Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceutical
- 4.1.1 Takeda Pharmaceutical Company Information
- 4.1.2 Takeda Pharmaceutical Business Overview
- 4.1.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Product Portfolio
- 4.1.5 Takeda Pharmaceutical Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Cardiovascular Disease Drugs Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Johnson＆Johnson
- 4.3.1 Johnson＆Johnson Company Information
- 4.3.2 Johnson＆Johnson Business Overview
- 4.3.3 Johnson＆Johnson Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Johnson＆Johnson Cardiovascular Disease Drugs Product Portfolio
- 4.3.5 Johnson＆Johnson Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Cardiovascular Disease Drugs Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Cardiovascular Disease Drugs Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Roche
- 4.6.1 Roche Company Information
- 4.6.2 Roche Business Overview
- 4.6.3 Roche Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Roche Cardiovascular Disease Drugs Product Portfolio
- 4.6.5 Roche Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Cardiovascular Disease Drugs Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Bayer
- 4.8.1 Bayer Company Information
- 4.8.2 Bayer Business Overview
- 4.8.3 Bayer Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bayer Cardiovascular Disease Drugs Product Portfolio
- 4.8.5 Bayer Recent Developments
- 4.9 AstraZeneca
- 4.9.1 AstraZeneca Company Information
- 4.9.2 AstraZeneca Business Overview
- 4.9.3 AstraZeneca Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 AstraZeneca Cardiovascular Disease Drugs Product Portfolio
- 4.9.5 AstraZeneca Recent Developments
- 4.10 United Therapeutics Corporation
- 4.10.1 United Therapeutics Corporation Company Information
- 4.10.2 United Therapeutics Corporation Business Overview
- 4.10.3 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 United Therapeutics Corporation Cardiovascular Disease Drugs Product Portfolio
- 4.10.5 United Therapeutics Corporation Recent Developments
- 4.11 Daiichi Sankyo Company Limited
- 4.11.1 Daiichi Sankyo Company Limited Company Information
- 4.11.2 Daiichi Sankyo Company Limited Business Overview
- 4.11.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Portfolio
- 4.11.5 Daiichi Sankyo Company Limited Recent Developments
- 4.12 Boehringer Ingelheim
- 4.12.1 Boehringer Ingelheim Company Information
- 4.12.2 Boehringer Ingelheim Business Overview
- 4.12.3 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Boehringer Ingelheim Cardiovascular Disease Drugs Product Portfolio
- 4.12.5 Boehringer Ingelheim Recent Developments
- 4.13 Astellas Pharma
- 4.13.1 Astellas Pharma Company Information
- 4.13.2 Astellas Pharma Business Overview
- 4.13.3 Astellas Pharma Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Astellas Pharma Cardiovascular Disease Drugs Product Portfolio
- 4.13.5 Astellas Pharma Recent Developments
- 4.14 Actelion Pharmaceuticals
- 4.14.1 Actelion Pharmaceuticals Company Information
- 4.14.2 Actelion Pharmaceuticals Business Overview
- 4.14.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Portfolio
- 4.14.5 Actelion Pharmaceuticals Recent Developments
5 Global Cardiovascular Disease Drugs Market Scenario by Region
- 5.1 Global Cardiovascular Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cardiovascular Disease Drugs Sales by Region: 2021-2032
- 5.2.1 Global Cardiovascular Disease Drugs Sales by Region: 2021-2026
- 5.2.2 Global Cardiovascular Disease Drugs Sales by Region: 2027-2032
- 5.3 Global Cardiovascular Disease Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Cardiovascular Disease Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Cardiovascular Disease Drugs Revenue by Region: 2027-2032
- 5.4 North America Cardiovascular Disease Drugs Market Facts & Figures by Country
- 5.4.1 North America Cardiovascular Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cardiovascular Disease Drugs Sales by Country (2021-2032)
- 5.4.3 North America Cardiovascular Disease Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cardiovascular Disease Drugs Market Facts & Figures by Country
- 5.5.1 Europe Cardiovascular Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cardiovascular Disease Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Cardiovascular Disease Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cardiovascular Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cardiovascular Disease Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cardiovascular Disease Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cardiovascular Disease Drugs Market Facts & Figures by Country
- 5.7.1 South America Cardiovascular Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cardiovascular Disease Drugs Sales by Country (2021-2032)
- 5.7.3 South America Cardiovascular Disease Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cardiovascular Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cardiovascular Disease Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cardiovascular Disease Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cardiovascular Disease Drugs Sales by Type (2021-2032)
- 6.1.1 Global Cardiovascular Disease Drugs Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Cardiovascular Disease Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Cardiovascular Disease Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Cardiovascular Disease Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cardiovascular Disease Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Cardiovascular Disease Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cardiovascular Disease Drugs Sales by Application (2021-2032)
- 7.1.1 Global Cardiovascular Disease Drugs Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Cardiovascular Disease Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Cardiovascular Disease Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Cardiovascular Disease Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cardiovascular Disease Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Cardiovascular Disease Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cardiovascular Disease Drugs Value Chain Analysis
- 8.1.1 Cardiovascular Disease Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cardiovascular Disease Drugs Production Mode & Process
- 8.2 Cardiovascular Disease Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cardiovascular Disease Drugs Distributors
- 8.2.3 Cardiovascular Disease Drugs Customers
9 Global Cardiovascular Disease Drugs Analyzing Market Dynamics
- 9.1 Cardiovascular Disease Drugs Industry Trends
- 9.2 Cardiovascular Disease Drugs Industry Drivers
- 9.3 Cardiovascular Disease Drugs Industry Opportunities and Challenges
- 9.4 Cardiovascular Disease Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst